Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: an observational cohort study

Table 6 Predictive values of biomarkers for ruling out AKI excluding patients with preoperative CKD^a

Biomarkers	AUC-ROC (95% CI)	Sensitivity	Specificity	Cutoff
Urine hepcidin, ng/mL
6 hours after CPB start	0.81 (0.67 to 0.96)	62.30%	100.00%	>545
24 hours after CPB start	0.83 (0.74 to 0.92)	79.70%	100.00%	>475
Urine hepcidin/urine creatinine, ng/mg
6 hours after CPB start	0.87 (0.75 to 0.99)	70.00%	100.00%	>2820
24 hours after CPB start	0.75 (0.57 to 0.94)	76.50%	80.00%	>1,762
Plasma hepcidin, ng/mL
6 hours after CPB start	0.70 (0.46 to 0.98)	69.00%	80.00%	>175
24 hours after CPB start	0.54 (0.23 to 0.86)	N/A	N/A	N/A

^aAKI, acute kidney injury; AUC, area under the curve; ROC, receiver operating characteristic; CKD, chronic kidney disease; CPB; cardiopulmonary bypass; N/A, values not presented for AUC-ROC <0.6. AKI is defined as Risk, Injury, Failure, Loss, End-stage renal disease classification of AKI (RIFLE) class R or worse including serum creatinine increase and urine output decrease.

ISSN: 1364-8535